LK101 / Likang Life Sci - LARVOL DELTA

A first-in-human study to evaluate a personalized neoantigen-based mRNA-loaded dendritic cell vaccine, in combination with ablation, in patients with hepatocellular carcinoma. (ASCO 2024) - P1 | "Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073."

Clinical • Combination therapy • IO biomarker • P1 data • Tumor-specific neoantigens • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pain • Solid Tumor • CD4 • CD8 • PD-1

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Beijing Likang Life Science and Tech Co., Ltd.

Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

China's first personalized tumor neoantigen vaccine has been approved by NMPA and entered the clinical stage (Sina Corp) - "Today, the data on the clinical trial implied license column of the Center for Drug Evaluation (CDE) of the State Drug Administration was updated. The personalized tumor neoantigen vaccine product of Beijing Likang Life Science and Technology Co., Ltd. —LK101 injection has been implicitly approved for clinical trials, and the indication is advanced solid tumors. This is the first personalized tumor neoantigen vaccine approved by NMPA to enter the clinical stage in China, and it is also the first fully personalized mRNA editing product approved to enter the clinical stage."

New trial • Oncology • Solid Tumor